Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients

OBJECTIVES: Emerging data suggest that the combination of tacrolimus and the CCR5 antagonist maraviroc, both cytochrome P450-3A4 substrates, may be effective in preventing graft-versus-host disease in patients undergoing allogeneic HSCT. This study evaluated whether a pharmacokinetic interaction exi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Antimicrob Chemother
Päätekijät: Ganetsky, Alex, Miano, Todd A., Hughes, Mitchell E., Vonderheide, Robert H., Porter, David L., Reshef, Ran
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2015
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4472330/
https://ncbi.nlm.nih.gov/pubmed/25881619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkv082
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia